Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Currently a phase I study of MEK162 in patients with biliary tract cancer is undergoing
InChi: InChI=1S/C39H32ClF10N7O5S2/c1-36(2
5-3(6)1-2-4(7)8/h2-3
which may result in the restoration of p53 signaling and
Oclacitinib - CAS# 1208319-26-9 Catalog No.:M9848-2 Currently a phase I studyOclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family members by 50% at concentrations (IC50 's) ranging from 10 to 99 nM and did not inhibit a panel of 38 non JAK kinases (IC50 's > 1000 nm). Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nm). Oclacitinib also inhibited the function of JAK1 dependent cytokines involved in allergy and